Document Detail

Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
MedLine Citation:
PMID:  18405171     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Hypertension is associated with hemostatic abnormalities and endothelial dysfunction. thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein linking coagulation and fibrinolysis. Objectives. We evaluated TAFI concentrations in patients with essential hypertension in relation to blood pressure. Additionally, we studied TAFI activator, thrombin activity (thrombin-antithrombin complexes--TAT, prothrombin fragments F1 + 2), thrombomodulin (TM)--a marker of endothelial cell injury, degree of plasmin generation (plasmin-antiplasmin complexes [PAP]), other markers of endothelial cell injury--von Willebrand factor (vWF). PATIENTS AND METHODS: Seventy-two patients with essential hypertension (27 untreated, 13 treated with enalapril (angiotensin-converting enzyme inhibitor [ACEI]), 32 with beta-blocker, betaxolol). In every hypertensive patients ambulatory blood pressure measurements and echocardiography were performed. RESULTS: All hypertensive patients did not differ with respect to age, creatinine, fibrinogen, D-dimers. In ACEI-treated patients a significantly higher TAFI concentration was observed when compared to beta-blocker-treated patients. In beta-blocker-treated patients both diastolic and systolic blood pressure were lower than in ACEI treated patients as well as ejection fraction, while serum triglycerides were higher. Diastolic blood pressure correlated significantly with TAFI concentrations in untreated patients (r = 0.27, p < 0.05), and in beta-blocker-treated patients (r = 0.25, p = 0.05), TAFI activity was inversely associated with interventricular septal diameter (r = -0.75, p < 0.01) in patients treated with ACEI. CONCLUSIONS: Elevated TAFI concentrations and enhanced thrombin generation in hypertensive patients may contribute to atherosclerosis progression in this population. Differences in the studied parameters may be due to a small sample size, monotherapy and potential effects of antihypertensive drugs on glicemia, ejection fraction and triglycerides.
Jolanta Ma?yszko; Justyna Tymcio
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Polskie Archiwum Medycyny Wewn?trznej     Volume:  118     ISSN:  0032-3772     ISO Abbreviation:  Pol. Arch. Med. Wewn.     Publication Date:    2008 Jan-Feb
Date Detail:
Created Date:  2008-04-14     Completed Date:  2008-05-16     Revised Date:  2010-04-01    
Medline Journal Info:
Nlm Unique ID:  0401225     Medline TA:  Pol Arch Med Wewn     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  36-41     Citation Subset:  IM    
Department of Nephrology and Transplantology, Medical University, Bia?ystok, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Biological Markers / blood
Blood Coagulation
Carboxypeptidase U / blood*
Endothelial Cells
Enzyme-Linked Immunosorbent Assay
Hypertension / blood*,  drug therapy*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biological Markers; EC U

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diabetes care and self-monitoring of type 2 diabetic patients in a rural district of West-Pomeranian...
Next Document:  Optimal treatment for patients after myocardial infarction: some current concepts and controversies.